March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) did not have a higher rate of death at one year compared with those who had their heart valve replaced via open-heart surgery, according to research presented at the American College of Cardiology (ACC) 2020 Annual Scientific Session.

PARTNER 3 trial shows positive results for Sapien 3 in low-risk surgical patients. #ACC20 #ACC2020 #Sapien3 #TAVR

March 30, 2020 — Low-risk patients undergoing transcatheter aortic valve repair (TAVR) at two years did just as well compared with those undergoing open heart valve replacement surgery in the PARTNER 3 low-risk trial. The two-year results presented at the American College of Cardiology (ACC) 2020 Annual Scientific Session

March 29, 2020 — Worse than expected outcomes were found for survival and quality of life among patients undergoing transcatheter aortic valve replacement (TAVR) at 34 medical centers in the United States. This was according to a study of 11 percent of U.S.

March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session. #ACC20 #ACC2020

March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session. The session was part of the virtual, online late-breaking presentations, since the live meeting was cancelled due to the spread of COVID-19. 

March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing transcatheter aortic valve replacement (TAVR) had a lower rate of bleeding complications without an increased risk of clotting-related complications compared to patients who took antiplatelet medication in addition to oral anticoagulants. This was the outcome of the POPULAR TAVR trial, presented as a late-breaking session at the American College of Cardiology (ACC) 2020 Scientific Session.[1]

March 28. 2020 — Among adults with heterozygous familial hypercholesterolemia, those who received the drug inclisiran had significantly lower levels of low-density lipoprotein (LDL) cholesterol than those who received placebo, with an infrequent dosing regimen and an acceptable safety profile. This was the conclusion of a pooled analysis of three ORION Phase III trials (ORION-9, 10, and 11). The results were presented at the virtual presentations of the late-breaking studies at the American College of Cardiology (ACC) 2020 conference.[1] 

March 28, 2020 — Women with coronary artery disease that reduces blood flow and oxygen to the heart muscle (ischemia) have significantly more chest pain caused by plaque build-up, yet less extensive disease as compared with men, according to new research presented at the American College of Cardiology (ACC) 2020 conference, being presented virtually onlinwe this year due to the COVID-19 pandemic.

March 28, 2020 — New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s dapagliflozin (Farxiga) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo, in patients with heart failure with reduced ejection fraction (HFrEF), irrespective of their bac

March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to patients following percutaneous coronary intervention (PCI) did not meet its primary endpoint of cutting in half the incidence of serious adverse cardiovascular events. This included heart attack and stroke, in the year following the procedure.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now